Moreover, the authors showed that a decrease in TTP expression was a negative prognostic marker in BC since patients with low tumor TTP expression were more likely to exhibit higher tumor grade, VEGF expression, and mortality from recurrent disease. This evidence concerns the gene ZFP36 and breast cancer.